Vertex Pharmaceuticals Inc. Stock Rises 5.6%, Outperforms Peers
Dow Jones2026/08/10 20:34This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Vertex Pharmaceuticals Inc. rose 5.6% to $523.91 on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.1% to 7,753.11 and Dow Jones Industrial Average falling 0.1% to 53,975.98.
This was the stock's second consecutive day of gains.
Vertex Pharmaceuticals Inc. closed 1.8% below its 52-week high of $533.67, which the company achieved on July 7th.
The stock outperformed some of its peers, as AbbVie Inc. rose 0.8% to $247.97, Krystal Biotech Inc. rose 1.6% to $331.59, and Arcturus Therapeutics Holdings Inc. fell 4.86% to $7.05.
Trading volume totaled 2.7 million, compared to the 50-day average of 1.6 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
August 10, 2026 16:34 ET (20:34 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Wall Street's "Great Rotation" Underway: AI Trading Fades, Tech Stocks Out of Favor, Capital Flows Shift to Defensive Sectors
Analysts point out that as investors shift their bets from high-risk technology sectors to defensive stocks, the market is currently in a "state of alert".
Barrick Gold (ABGC.US) applies for U.S. IPO, aiming to raise up to 6 billion dollars
American Barrick Gold has submitted its initial public offering (IPO) application to the U.S. Securities and Exchange Commission (SEC).
Japanese stocks closed up 1.31%
Crypto prices
More
